Biological Identity of Nanoparticles In Vivo: Clinical Implications of the Protein Corona

Trends in Biotechnology

Volumn 35, Issue 3, 2017, Pages 257-264

  Caracciolo, Giulio ^a   Farokhzad, Omid C ^b,c   Mahmoudi, Morteza ^b,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

biological identity; nanobio interfaces; nanoparticles; protein corona

Indexed keywords

MEDICAL APPLICATIONS; NANOPARTICLES; PHYSIOLOGY; PROTEINS;

BIOLOGICAL IDENTITY; BIOLOGICAL INTERACTIONS; BIOMEDICAL APPLICATIONS; NANOBIO; PHYSIOLOGICAL ENVIRONMENT; PROTEIN CONCENTRATIONS; PROTEIN CORONAS; STRUCTURE-ACTIVITY RELATION;

PHYSIOLOGICAL MODELS;

NANOPARTICLE; PROTEIN CORONA;

CELL INTERACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ANIMAL; MEDICAL RESEARCH; MOUSE;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; MICE; NANOPARTICLES; PROTEIN CORONA;

EID: 84994772430     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2016.08.011     Document Type: Review

References (55)

1. 1 Bazak, R., et al. Cancer active targeting by nanoparticles: a comprehensive review of literature. J. Cancer Res. Clin. Oncol. 141 (2015), 769–784.
2. 2 Cole, J.T., Holland, N.B., Multifunctional nanoparticles for use in theranostic applications. Drug Deliv. Transl. Res. 5 (2015), 295–309.
3. 3 Satterlee, A.B., Huang, L., Current and future theranostic applications of the lipid-calcium-phosphate nanoparticle platform. Theranostics 6 (2016), 918–929.
4. 4 Chinen, A.B., et al. Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence. Chem. Rev. 115 (2015), 10530–10574.
5. 5 Smith, J.D., et al. Nanoparticles as synthetic vaccines. Curr. Opin. Biotechnol. 34 (2015), 217–224.
6. 6 Bisgaier, C.L., et al. Effects of apolipoproteins A-IV and AI on the uptake of phospholipid liposomes by hepatocytes. J. Biol. Chem. 264 (1989), 862–866.
7. 7 Lück, M., et al. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J. Biomed. Mater. Res. 39 (1998), 478–485.
8. 8 Zelphati, O., et al. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim. Biophys. Acta 1390 (1998), 119–133.
9. 9 Deng, Z.J., et al. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat. Nanotechnol. 6 (2011), 39–44.
10. 10 Mahon, E., et al. Designing the nanoparticle–biomolecule interface for ‘targeting and therapeutic delivery’. J. Control. Release 161 (2012), 164–174.
11. 11 Moghimi, S.M., et al. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001), 283–318.
12. 12 Cedervall, T., et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew. Chem. Int. Ed. 46 (2007), 5754–5756.
13. 13 Lundqvist, M., et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 14265–14270.
14. 14 Monopoli, M.P., et al. Nanobiotechnology: nanoparticle coronas take shape. Nat. Nanotechnol. 6 (2011), 11–12.
15. 15 Docter, D., et al. The nanoparticle biomolecule corona: lessons learned–challenge accepted?. Chem. Soc. Rev. 44 (2015), 6094–6121.
16. 16 Barrán-Berdón, A.L., et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir 29 (2013), 6485–6494.
17. 17 Mahmoudi, M., Protein corona: the golden gate to clinical applications of nanoparticles. Int. J. Biochem. Cell. Biol. 75 (2016), 141–142.
18. 18 Caracciolo, G., Liposome–protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. Nanomedicine 11 (2015), 543–557.
19. 19 Caracciolo, G., et al. Lipid composition: a ‘key factor’ for the rational manipulation of the liposome-protein corona by liposome design. RSC Adv. 5 (2015), 5967–5975.
20. 20 Hamad-Schifferli, K., Exploiting the novel properties of protein coronas: emerging applications in nanomedicine. Nanomedicine 10 (2015), 1663–1674.
21. 21 Monopoli, M.P., et al. Physical − chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133 (2011), 2525–2534.
22. 22 Nel, A.E., et al. Understanding biophysicochemical interactions at the nano–bio interface. Nat. Mater. 8 (2009), 543–557.
23. 23 Caracciolo, G., et al. The liposome–protein corona in mice and humans and its implications for in vivo delivery. J. Mater. Chem. B 2 (2014), 7419–7428.
24. 24 Mirshafiee, V., et al. The importance of selecting a proper biological milieu for protein corona analysis in vitro: human plasma versus human serum. Int. J. Biochem. Cell Biol. 75 (2015), 188–195.
25. 25 Mahmoudi, M., et al. Temperature: the ‘ignored’ factor at the nanobio interface. ACS Nano 7 (2013), 6555–6562.
26. 26 Mahmoudi, M., et al. Variation of protein corona composition of gold nanoparticles following plasmonic heating. Nano Lett. 14 (2013), 6–12.
27. 27 Tenzer, S., et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8 (2013), 772–781.
28. 28 Polyak, B., Cordovez, B., How can we predict behavior of nanoparticles in vivo?. Nanomedicine 1 (2016), 189–192.
29. 29 Corbo, C., et al. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine 11 (2016), 81–100.
30. 30 Maiolo, D., et al. Nanomedicine delivery: does protein corona route to the target or off road?. Nanomedicine 10 (2015), 3231–3247.
31. 31 Wilhelm, S., et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater., 1, 2016, 16014.
32. 32 Sakulkhu, U., et al. Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. Nanoscale 6 (2014), 11439–11450.
33. 33 Hadjidemetriou, M., et al. In vivo biomolecule corona around blood-circulating, clinically-used and antibody–targeted lipid bilayer nanoscale vesicles. ACS Nano 9 (2015), 8142–8156.
34. 34 Hadjidemetriou, M., et al. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. Nanoscale 8 (2016), 6948–6957.
35. 35 Pozzi, D., et al. The biomolecular corona of nanoparticles in circulating biological media. Nanoscale 7 (2015), 13958–13966.
36. 36 Braun, N.J., et al. Modification of the protein corona–nanoparticle complex by physiological factors. Mater. Sci. Eng. C 64 (2016), 34–42.
37. 37 Palchetti, S., et al. The protein corona of circulating PEGylated liposomes. Biochim. Biophys. Acta 1858 (2016), 189–196.
38. 38 Mo, Z-C., et al. A high-density lipoprotein-mediated drug delivery system. Adv. Drug Deliv. Rev., 2016, 10.1016/j.addr.2016.04.030 Published online May 18, 2016.
39. 39 Westmeier, D., et al. The bio-corona and its impact on nanomaterial toxicity. Eur. J. Nanomed. 7 (2015), 153–168.
40. 40 Walkey, C.D., Chan, W.C.W., Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41 (2012), 2780–2799.
41. 41 Monopoli, M.P., et al. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7 (2012), 779–786.
42. 42 Lai, Z.W., et al. Emerging techniques in proteomics for probing nano–bio interactions. ACS Nano 6 (2012), 10438–10448.
43. 43 Mahmoudi, M., et al. Protein–nanoparticle interactions: opportunities and challenges. Chem. Rev. 111 (2011), 5610–5637.
44. 44 Walkey, C.D., et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8 (2014), 2439–2455.
45. 45 Le, T.C., et al. An experimental and computational approach to the development of ZnO nanoparticles that are safe by design. Small 12 (2016), 3568–3577.
46. 46 Lin, Z., et al. A computational framework for interspecies pharmacokinetics, exposure and toxicity assessment of gold nanoparticles. Nanomedicine 11 (2016), 107–119.
47. 47 Burello, E., Worth, A.P., QSAR modeling of nanomaterials. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3 (2011), 298–306.
48. 48 Winkler, D.A., et al. Applying quantitative structure–activity relationship approaches to nanotoxicology: current status and future potential. Toxicology 313 (2013), 15–23.
49. 49 Shao, C-Y., et al. Dependence of QSAR models on the selection of trial descriptor sets: a demonstration using nanotoxicity endpoints of decorated nanotubes. J. Chem. Inf. Model. 53 (2013), 142–158.
50. 50 Liu, R., et al. Prediction of nanoparticles-cell association based on corona proteins and physicochemical properties. Nanoscale 7 (2015), 9664–9675.
51. 51 Gajewicz, A., et al. Towards understanding mechanisms governing cytotoxicity of metal oxides nanoparticles: hints from nano-QSAR studies. Nanotoxicology 9 (2015), 313–325.
52. 2 nanoparticles. Chemosphere 144 (2016), 995–1001.
53. 53 Kamath, P., et al. Predicting cell association of surface-modified nanoparticles using protein corona structure-activity relationships (PCSAR). Curr. Top. Med. Chem. 15 (2015), 1930–1937.
54. 54 Mahmoudi, M., et al. Crucial role of the protein corona for the specific targeting of nanoparticles. Nanomedicine 10 (2015), 215–226.
55. 55 Kelly, P.M., et al. Mapping protein binding sites on the biomolecular corona of nanoparticles. Nat. Nanotechnol. 10 (2015), 472–479.